Tuberculosis is killing more people than thought, yet governments are not doing enough to bring the debilitating infectious disease under control

he latest WHO figures show TB has been taking a much greater cost in India than previously considered and that the number of instances worldwide last year was 10.4m

The latest WHO figures show TB has been taking a much greater cost in India than previously considered and that the number of instances worldwide last year was 10.4m, upwards from the 9.6m estimated before more in-depth investigations were done.

The disease claims the lives of 1.8 million individuals worldwide each year, not the 1.5 million it was previously thought.

Drug-resistant TB, which is less easy and very expensive to treat with blends of the most recent antibiotics, has also climbed, to over half a million cases internationally.

Director general of the WHO, Dr. Margaret Chan, warned that if the world was to have any hope of stopping the disease in its tracks more needed to be done.

“There must be a massive scale-up of attempts, or countries will continue to run behind this fatal epidemic, and these challenging goals will be missed.”

The UN has set a target of cutting TB deaths by 90% and cases of the disease.

Unlike Aids and malaria, most TB cases are not in the poorest states so there's less funding available in the wealthy states, which give through conduits like the Global Fund to Fight Aids, Tuberculosis and Malaria only to the lowest – even though they face the threat of the disease which spreads in water droplets and cannot be confined to specific countries within an era of international journey.

The US does not have specific financing for TB programs as it does for HIV, while the EU places in little by comparison with contributions for HIV and malaria.

India has about a quarter of all the cases on the planet, followed by Indonesia and then China, which has about 10% each. Nigeria and Pakistan, each account for 5% of instances and South Africa, has a little less.

“These [six] countries have 60% of the burden. TB is just not said Dr Mario Raviglione, director of WHO’s worldwide TB program. “It is a disorder of the Brics [ Brazil, Russia, India, China and South Africa] and middle-income countries. We're talking about a disorder that finally is funded mainly by national financing.”

But health ministers cannot argue the case for resources for TB with governments that feel they have other priorities.

“We're saying there is a dismal advancement on devotion,” said Raviglione. “TB isn't something that will only come down if you have development. It is a dangerous game. It is not going to go. It'll take generations.”

The results are not going to be understood until at least 2019 although the government has agreed to conduct one. But among the wealthiest Indian states, a survey in Gujarat established a much higher prevalence of TB than had been believed and collectively with other evidence, it has not been impossible to think of a better estimate than in previous years.

Work continues to be going on to encourage doctors in the private sector to report TB cases, which they aren't obliged to do and have not done before. In the slums of Mumbai, healers and Ayurvedic doctors who see most of the patients are supported to give out the free antibiotics to treat TB alongside conventional treatments, and to report the numbers of patients they see. A digital reporting system has been introduced with some success.

India gains praise from WHO, but its activities have served to highlight the scale of the difficulty. Of the 10.4m cases global, just 6.1m were found and treated in 2015. Those undetected threat is passing the bacteria that creates TB to their families. Countries don't have the accelerated testing equipment they need.

There's particular concern over drug-resistant TB, which changes 580,000 individuals. Just half of individuals who get a strain resistant to the conventional antibiotic combination of drugs survive. Only one in five of people that have TB that is resistant gets the newer mix of antibiotics that can heal it.

“There ’s an effective new regimen accessible for treating multidrug-resistant TB, and that needs to get to patients as fast as possible. If we're to end the TB outbreak by 2035, we should triple our rate of improvement in a short period and that means tackling MDR-TB head on.”